![]() |
Name |
Occidol
|
Molecular Formula | C15H22O | |
IUPAC Name* |
2-(5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propan-2-ol
|
|
SMILES |
CC1=C2CCC(CC2=C(C=C1)C)C(C)(C)O
|
|
InChI |
InChI=1S/C15H22O/c1-10-5-6-11(2)14-9-12(15(3,4)16)7-8-13(10)14/h5-6,12,16H,7-9H2,1-4H3
|
|
InChIKey |
AFBBWQXTLZVDEE-UHFFFAOYSA-N
|
|
Synonyms |
Occidol; Q67880033
|
|
CAS | NA | |
PubChem CID | 11020369 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 218.33 | ALogp: | 3.5 |
HBD: | 1 | HBA: | 1 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 20.2 | Aromatic Rings: | 2 |
Heavy Atoms: | 16 | QED Weighted: | 0.756 |
Caco-2 Permeability: | -4.416 | MDCK Permeability: | 0.00002440 |
Pgp-inhibitor: | 0.099 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.915 |
30% Bioavailability (F30%): | 0.867 |
Blood-Brain-Barrier Penetration (BBB): | 0.868 | Plasma Protein Binding (PPB): | 93.53% |
Volume Distribution (VD): | 1.72 | Fu: | 5.24% |
CYP1A2-inhibitor: | 0.276 | CYP1A2-substrate: | 0.869 |
CYP2C19-inhibitor: | 0.269 | CYP2C19-substrate: | 0.901 |
CYP2C9-inhibitor: | 0.167 | CYP2C9-substrate: | 0.871 |
CYP2D6-inhibitor: | 0.038 | CYP2D6-substrate: | 0.898 |
CYP3A4-inhibitor: | 0.094 | CYP3A4-substrate: | 0.425 |
Clearance (CL): | 7.811 | Half-life (T1/2): | 0.24 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.078 |
Drug-inuced Liver Injury (DILI): | 0.038 | AMES Toxicity: | 0.009 |
Rat Oral Acute Toxicity: | 0.008 | Maximum Recommended Daily Dose: | 0.116 |
Skin Sensitization: | 0.142 | Carcinogencity: | 0.107 |
Eye Corrosion: | 0.152 | Eye Irritation: | 0.934 |
Respiratory Toxicity: | 0.03 |